1Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
2Gynecologic Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea
3Department of Cancer Control, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
4Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
5Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea
Copyright © 2016 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Values are presented as mean±standard deviation. EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module; FSFI, Female Sexual Function Index.
Study (year) | Study period | Inclusion criteria | Exclusion criteria | No. of participants | Age at study | FSFI total score | Years since diagnosis | Measurement | Result |
---|---|---|---|---|---|---|---|---|---|
Frumovitz et al. (2005) [14], USA | NA | Stage I | Combination of surgical and radiation therapies | RH (n=37) | 43.6 | 25.1 | 7.5 | FSFI, SF-12, BSI-18, menopause scale, A-DAS, CARES | Radiotherapy deteriorated sexual functioning |
Age < 55 yr at the treatment | CCRT | Radiotherapy (n=37) | 46.9 | 17.1 | 7.0 | - | 63% of those sexually active before having cancer remained sexually active after treatment | ||
Treatment at least 5 yr previously | Disease recurrence | Control (n=40) | 42.8 | 26.4 | - | - | Sexual functioning and QoL did not differ significantly between surgery and control | ||
Disease-free state | Treated for other malignancies | - | - | - | - | - | - | ||
Surgery or radiotherapy | - | - | - | - | - | - | - | ||
Carter et al. (2008) [13], USA | Feb 2004-Jan 2008 | Stage I | NA | RT (n=30) | 18-49 | NA | NA | FSFI, FACT-CX, CES-D | At the 6-mo follow-up assessment, 70% of the women were sexually active |
Age 18-49 yr | - | - | - | - | - | - | Postoperative dyspareunia decreased over time | ||
Serati et al. (2009) [15], Italy | Jan 2003-Dec 2007 | Stage IB or IIA | Non-sexually active women | RH (n=38) | 47 (24-71) | 17.2 | NA | FSFI | Radical hysterectomy deteriorated sexual functioning |
Received RH | Severe mental illness | Laparoscopy (n=20) | 45.0 (24-69) | 10.8 | - | - | Laparoscopic surgery did not show any benefit on sexuality over the abdominal surgery | ||
- | Severe physical handicap | Laparotomy (n=18) | 44.5 (25-68) | 21.9 | - | - | - | ||
- | Pregnant | Control (n=35) | 45 (24-69) | 30.7 | - | - | - | ||
Carter et al. (2010) [12], USA | Feb 2004-Jan 2008 | Stage IA1-IB2 | NA | RT (n=33) | 32.6 | Baseline vs. after 2 yr 17.4 vs. 21.9 | NA | FSFI, FACT-CX, CES-D, IES | Sexual functioning and QoL did not differ significantly by surgical type |
Age 18-45 yr | - | RH (n=19) | 37.6 | Baseline vs. after 2 yr 15.7 vs. 22.6 | - | - | - | ||
Tsai et al. (2011) [17], Taiwan | NA | CIS or above age ≥ 20 yr | NA | CC (n=105) | 54.3 (28-78) | NA | NA | FSFI | Older age (Cl, 1.07-1.25) |
Sexual activity 3 yr before the diagnosis | - | - | - | - | - | - | Level of education (≤ 9th grade) (CI, 1.51-10.37) | ||
Song et al. (2012) [16], Korea | Aug 2010-Nov 2010 | Stage IA-IB1 | Refuse to participate in the survey | Conization (n=39) | 34.7 | 30.7 | 2.5 | FSFI | Radical trachelectomy and hysterectomy deteriorated sexual function than conization |
Age < 40 yr | Laparotomic approach | RT (n=18) | 34.7 | 21.7 | 2.5 | - | - | ||
Sexual activity preoperative | Oophorectomy with radical surgery | RH (n=24) | 36.8 | 22.4 | 2.3 | - | - | ||
- | Adjuvant radiation and/or chemotherapy | - | - | - | - | - | - | ||
- | Disease recurrence | - | - | - | - | - | - | ||
Lee et al., Korea | Feb 2013-Jan 2014 | Stage I-IV | Refuse to participate in the survey | CC (n=104) | 47.0 (24-70) | 23.0 | 3.7 | FSFI, EORTC QLQ-C30, EORTC QLQ-CX24 | Body image and lymphedema were more problematic in cervical cancer survivors |
Age ≥ 18 yr | - | Control (n=104) | 48.9 (24-66) | 21.9 | - | - | Sexual functioning was not impaired | ||
Sexual activity within 3 mo | - | - | - | - | - | - | - | ||
Disease-free state | - | - | - | - | - | - | - |
NA, not available; RH, radical hysterectomy; SF-12, Short Form 12; BSI, Brief Symptom Index-18; A-DAS, Abbreviated Dyadic Adjustment Scale; CARES, Cancer Rehabilitation Evaluation System; CCRT, concurrent chemoradiotherapy; QoL, quality of life; RT, radical trachelectomy; FACT, Functional Assessment of Cancer Therapy; CES-D, Center for Epidemiology Studies Depression; IES, Impact of Event Scale; CIS, carcinoma in situ; CC, cervical cancer; CI, confidence interval; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24, EORTC QLQ-Cervical Cancer Module.
Characteristic | Cervical cancer survivor (n=104) | Control group (n=104) | p-value |
---|---|---|---|
Age (yr) | 46.95±7.98 | 48.86±8.53 | 0.098 |
Marital status | |||
Single/Separated/Widowed | 14 (13.5) | 11 (10.6) | 0.670 |
Married | 90 (86.5) | 93 (89.4) | |
Education (yr) | |||
≤ 9 | 12 (11.5) | 14 (13.5) | 0.834 |
> 9 | 92 (88.5) | 90 (86.5) | |
Family income ($/mo) | |||
≤ 2,000 | 13 (12.5) | 16 (15.4) | 0.833 |
> 2,000 to ≤ 4,000 | 45 (43.3) | 44 (42.3) | |
> 4,000 | 46 (44.2) | 44 (42.3) | |
Occupational status | |||
Yes | 45 (43.3) | 49 (47.1) | 0.676 |
No | 59 (56.7) | 55 (52.9) | |
Menopause status | |||
Yes | 76 (73.1) | 67 (64.4) | 0.231 |
No | 28 (26.9) | 37 (35.6) | |
Regular exercise | |||
Yes | 50 (48.1) | 45 (43.3) | 0.578 |
No | 54 (51.9) | 59 (56.7) |
Characteristic | Cervical cancer survivor (n=104) |
---|---|
FIGO stage | |
Ⅰ | 81 (77.9) |
Ⅱ | 18 (17.3) |
Ⅲ | 4 (3.8) |
Ⅳ | 1 (1.0) |
Histology | |
Squamous cell carcinoma | 81 (77.9) |
Adenocarcinoma | 22 (21.2) |
Small cell carcinoma | 1 (1.0) |
Survival period (yr) | |
≤ 2 | 31 (29.8) |
> 2 to ≤ 5 | 39 (37.5) |
> 5 | 34 (32.7) |
Type of treatment | |
Conization only | 14 (13.5) |
Simple hysterectomy only | 8 (7.7) |
Radical hysterectomy only | 43 (41.3) |
Conization+R+C | 2 (1.9) |
Simple hysterectomy+C | 1 (1.0) |
Simple hysterectomy+R+C | 2 (1.9) |
Radical hysterectomy+C | 4 (3.8) |
Radical hysterectomy+R | 6 (5.8) |
Radical hysterectomy+R+C | 13 (12.5) |
Staging surgery only+R | 3 (2.9) |
R only | 1 (1.0) |
R+C | 7 (6.7) |
Type of surgery | |
Conization | 16 (15.4) |
Simple hysterectomy | 11 (10.6) |
Radical hysterectomy | 66 (63.5) |
Staging surgery | 3 (2.9) |
No surgery | 8 (7.7) |
Status of ovaries | |
Ovaries in situ | 79 (76.0) |
Ovarian transposition | 1 (1.0) |
Bilateral oophorectomy | 18 (17.3) |
Unilateral oophorectomy | 6 (5.8) |
Domain | Cervical cancer survivor (n=104) | Control group (n=104) | p-value |
---|---|---|---|
EORTC QLQ-C30 | |||
Physical functioning | 79.3±15.5 | 80.6±14.5 | 0.539 |
Role functioning | 85.7±19.8 | 87.3±17.1 | 0.533 |
Emotional functioning | 77.9±20.9 | 76.8±21.9 | 0.706 |
Cognitive functioning | 77.9±17.6 | 78.4±16.9 | 0.841 |
Social functioning | 83.2±24.3 | 88.1±21.1 | 0.117 |
Fatigue | 35.1±22.7 | 39.9±23.9 | 0.147 |
Nausea and vomiting | 5.8±13.3 | 8.7±16.9 | 0.173 |
Pain | 15.2±19.6 | 19.4±21.7 | 0.147 |
Dyspnea | 12.2±20.8 | 12.8±19.9 | 0.820 |
Insomnia | 23.4±27.8 | 25.3±26.9 | 0.613 |
Appetite loss | 11.2±19.5 | 10.3±18.0 | 0.712 |
Constipation | 25.0±28.2 | 21.8±28.5 | 0.416 |
Diarrhea | 14.7±21.2 | 11.9±22.2 | 0.339 |
Financial difficulties | 11.2±20.6 | 10.3±21.3 | 0.741 |
Global health status | 64.5±20.2 | 59.9±20.5 | 0.108 |
EORTC QLQ-CX24 | |||
Body image | 73.1±25.2 | 79.6±18.8 | 0.036 |
Symptom experience | 12.1±10.1 | 10.5±8.9 | 0.244 |
Lymphedema | 20.2±28.0 | 12.2±21.8 | 0.022 |
Peripheral neuropathy | 22.4±28.4 | 17.0±23.2 | 0.132 |
Menopausal symptoms | 20.5±27.2 | 17.3±23.2 | 0.362 |
Sexual activity | 32.1±24.5 | 30.1±26.6 | 0.583 |
Sexual enjoyment | 40.1±24.3 | 37.8±25.9 | 0.537 |
Sexual/Vaginal functioning | 80.6±20.6 | 85.4±16.8 | 0.077 |
Sexual worry | 26.6±28.0 | 22.0±24.9 | 0.214 |
FSFI | |||
Desire | 3.0±1.0 | 2.9±1.1 | 0.617 |
Arousal | 3.5±1.3 | 3.2±1.6 | 0.232 |
Lubrication | 4.1±1.7 | 4.0±1.9 | 0.696 |
Orgasm | 3.9±1.5 | 3.7±1.8 | 0.356 |
Satisfaction | 4.0±0.7 | 3.9±1.2 | 0.363 |
Pain | 4.5±1.7 | 4.1±2.0 | 0.214 |
Total | 23.0±6.6 | 21.9±8.2 | 0.300 |
Study (year) | Study period | Inclusion criteria | Exclusion criteria | No. of participants | Age at study | FSFI total score | Years since diagnosis | Measurement | Result |
---|---|---|---|---|---|---|---|---|---|
Frumovitz et al. (2005) [14], USA | NA | Stage I | Combination of surgical and radiation therapies | RH (n=37) | 43.6 | 25.1 | 7.5 | FSFI, SF-12, BSI-18, menopause scale, A-DAS, CARES | Radiotherapy deteriorated sexual functioning |
Age < 55 yr at the treatment | CCRT | Radiotherapy (n=37) | 46.9 | 17.1 | 7.0 | - | 63% of those sexually active before having cancer remained sexually active after treatment | ||
Treatment at least 5 yr previously | Disease recurrence | Control (n=40) | 42.8 | 26.4 | - | - | Sexual functioning and QoL did not differ significantly between surgery and control | ||
Disease-free state | Treated for other malignancies | - | - | - | - | - | - | ||
Surgery or radiotherapy | - | - | - | - | - | - | - | ||
Carter et al. (2008) [13], USA | Feb 2004-Jan 2008 | Stage I | NA | RT (n=30) | 18-49 | NA | NA | FSFI, FACT-CX, CES-D | At the 6-mo follow-up assessment, 70% of the women were sexually active |
Age 18-49 yr | - | - | - | - | - | - | Postoperative dyspareunia decreased over time | ||
Serati et al. (2009) [15], Italy | Jan 2003-Dec 2007 | Stage IB or IIA | Non-sexually active women | RH (n=38) | 47 (24-71) | 17.2 | NA | FSFI | Radical hysterectomy deteriorated sexual functioning |
Received RH | Severe mental illness | Laparoscopy (n=20) | 45.0 (24-69) | 10.8 | - | - | Laparoscopic surgery did not show any benefit on sexuality over the abdominal surgery | ||
- | Severe physical handicap | Laparotomy (n=18) | 44.5 (25-68) | 21.9 | - | - | - | ||
- | Pregnant | Control (n=35) | 45 (24-69) | 30.7 | - | - | - | ||
Carter et al. (2010) [12], USA | Feb 2004-Jan 2008 | Stage IA1-IB2 | NA | RT (n=33) | 32.6 | Baseline vs. after 2 yr 17.4 vs. 21.9 | NA | FSFI, FACT-CX, CES-D, IES | Sexual functioning and QoL did not differ significantly by surgical type |
Age 18-45 yr | - | RH (n=19) | 37.6 | Baseline vs. after 2 yr 15.7 vs. 22.6 | - | - | - | ||
Tsai et al. (2011) [17], Taiwan | NA | CIS or above age ≥ 20 yr | NA | CC (n=105) | 54.3 (28-78) | NA | NA | FSFI | Older age (Cl, 1.07-1.25) |
Sexual activity 3 yr before the diagnosis | - | - | - | - | - | - | Level of education (≤ 9th grade) (CI, 1.51-10.37) | ||
Song et al. (2012) [16], Korea | Aug 2010-Nov 2010 | Stage IA-IB1 | Refuse to participate in the survey | Conization (n=39) | 34.7 | 30.7 | 2.5 | FSFI | Radical trachelectomy and hysterectomy deteriorated sexual function than conization |
Age < 40 yr | Laparotomic approach | RT (n=18) | 34.7 | 21.7 | 2.5 | - | - | ||
Sexual activity preoperative | Oophorectomy with radical surgery | RH (n=24) | 36.8 | 22.4 | 2.3 | - | - | ||
- | Adjuvant radiation and/or chemotherapy | - | - | - | - | - | - | ||
- | Disease recurrence | - | - | - | - | - | - | ||
Lee et al., Korea | Feb 2013-Jan 2014 | Stage I-IV | Refuse to participate in the survey | CC (n=104) | 47.0 (24-70) | 23.0 | 3.7 | FSFI, EORTC QLQ-C30, EORTC QLQ-CX24 | Body image and lymphedema were more problematic in cervical cancer survivors |
Age ≥ 18 yr | - | Control (n=104) | 48.9 (24-66) | 21.9 | - | - | Sexual functioning was not impaired | ||
Sexual activity within 3 mo | - | - | - | - | - | - | - | ||
Disease-free state | - | - | - | - | - | - | - |
Values are presented as mean±standard deviation or number (%).
Values are presented as number (%). Staging surgery was defined as performance of pelvic lymphadenectomy and para-aortic lymphadenectomy without hysterectomy. FIGO, International Federation of Gynecology and Obstetrics; R, radiotherapy; C, chemotherapy.
Values are presented as mean±standard deviation. EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module; FSFI, Female Sexual Function Index.
NA, not available; RH, radical hysterectomy; SF-12, Short Form 12; BSI, Brief Symptom Index-18; A-DAS, Abbreviated Dyadic Adjustment Scale; CARES, Cancer Rehabilitation Evaluation System; CCRT, concurrent chemoradiotherapy; QoL, quality of life; RT, radical trachelectomy; FACT, Functional Assessment of Cancer Therapy; CES-D, Center for Epidemiology Studies Depression; IES, Impact of Event Scale; CIS, carcinoma